FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | IN BENEFICIAL | OWNERSHIP |
|-----------|-------------------|---------------|------------------|

| OMB Number: | 3235-0287 |
|----------------------|-----------|
| Estimated average bu | ırden |
| hours per response: | 0.5 |

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | _ | | | | | | | | | | | | | | |
|--|---|--|----------------|---|---|-----|---------|---|--|---------|---|---------------|---|--------|---|---|---|--|--------------|----|
| 1. Name and Address of Reporting Person* | | | | CU | 2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner | | | | | | | |
| (Last) (First) (Middle) 2525 WEST END AVE. SUITE 950 | | | 3. D | INC [CPIX] 3. Date of Earliest Transaction (Month/Day/Year) 05/24/2010 | | | | | | | | | X | Office | , | Other (speci below) n and CEO | | | | |
| (Street) NASHVI (City) | LLE T | | 37203 Zip) | | - 4. If | Ame | ndment, | Date of | f Origina | l Filed | i (Month/Da | ay/Yea | ar) | | . Indivi ine) X | Form | r Joint/Group n filed by One n filed by Mor on | e Rep | oorting Pers | on |
| | | Tabl | e I - Noi | n-Deriv | ative | Se | curitie | s Acq | quired, | Dis | posed o | f, or | r Ben | eficia | ally (| Owne | ed | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da | | | | Execution Date, | | | | ies Acquired (A) Of (D) (Instr. 3, 4 | | | 1 and Secui Benet | | rities F ficially (ed Following (| | ownership m: Direct or Indirect nstr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | |
| | | | | | | | | Code | v | Amount | | (A) or (D) | Price | . 1 | Transa | ransaction(s) Instr. 3 and 4) | | | (111501. 4) | |
| Common stock 05/24/2 | | | | 1/2010 | 2010 P 15,500 A \$ | | \$6.6 | 66 ⁽¹⁾ | 6 ⁽¹⁾ 5,440,845 | | | D | | | | | | | | |
| | | Та | | | | | | | | | osed of, onvertib | | | | | ned | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | Date Execution | n Date, Transacti Code (Ins | | | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) | | | | ivative urity tr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(: (Instr. 4) | Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | | Date Exercisa | | Expiration Date | Title | of | nber | | | | | | |

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$6.579 to \$6.71. The reporting person undertakes to provide to Cumberland Pharmaceuticals, any security holder of Cumberland Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

Remarks:

A.J. Kazimi by: /s/ David L. Lowrance as attorney-in-fact

05/25/2010

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.